Chinese medicine for coronavirus disease 2019 as complementary therapy: A protocol for a systematic review and meta-analysis.
Identifieur interne : 000792 ( Main/Exploration ); précédent : 000791; suivant : 000793Chinese medicine for coronavirus disease 2019 as complementary therapy: A protocol for a systematic review and meta-analysis.
Auteurs : Min Zhou [République populaire de Chine] ; Qijun Liang ; Qiulan Pei ; Fan Xu ; Hang WenSource :
- Medicine [ 1536-5964 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Betacoronavirus (MeSH), Essais contrôlés randomisés comme sujet (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (thérapie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Mâle (MeSH), Médecine traditionnelle chinoise (méthodes), Médicaments issus de plantes chinoises (usage thérapeutique), Méta-analyse comme sujet (MeSH), Odds ratio (MeSH), Pandémies (MeSH), Plan de recherche (MeSH), Pneumopathie virale (thérapie), Pneumopathie virale (virologie), Revues systématiques comme sujet (MeSH), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Thérapies complémentaires (méthodes), Études prospectives (MeSH).
- MESH :
- méthodes : Médecine traditionnelle chinoise, Thérapies complémentaires.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus.
- usage thérapeutique : Médicaments issus de plantes chinoises.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Adulte, Adulte d'âge moyen, Betacoronavirus, Essais contrôlés randomisés comme sujet, Femelle, Humains, Mâle, Méta-analyse comme sujet, Odds ratio, Pandémies, Plan de recherche, Revues systématiques comme sujet, Résultat thérapeutique, Sujet âgé, Études prospectives.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Betacoronavirus (MeSH), Complementary Therapies (methods), Coronavirus Infections (drug therapy), Coronavirus Infections (therapy), Coronavirus Infections (virology), Drugs, Chinese Herbal (therapeutic use), Female (MeSH), Humans (MeSH), Male (MeSH), Medicine, Chinese Traditional (methods), Meta-Analysis as Topic (MeSH), Middle Aged (MeSH), Odds Ratio (MeSH), Pandemics (MeSH), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), Prospective Studies (MeSH), Randomized Controlled Trials as Topic (MeSH), Research Design (MeSH), Systematic Reviews as Topic (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , therapeutic use : Drugs, Chinese Herbal.
- drug therapy : Coronavirus Infections.
- methods : Complementary Therapies, Medicine, Chinese Traditional.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Betacoronavirus, Female, Humans, Male, Meta-Analysis as Topic, Middle Aged, Odds Ratio, Pandemics, Prospective Studies, Randomized Controlled Trials as Topic, Research Design, Systematic Reviews as Topic, Treatment Outcome.
Abstract
BACKGROUND
The aim of this systematic review and meta-analysis is to assess effectiveness and safety of Chinese medicine (CM) as complementary therapy in treating coronavirus disease 2019 (COVID-19).
METHODS
The following databases will be searched: PubMed, Cochrane, Embase, China National Knowledge Infrastructure, Chinese Science and Technology Periodical Database, and Wanfang database from October 1, 2019 to March 1, 2020. Randomized trials and quasi-randomized or prospective controlled clinical trials of CM that reported data on COVID-19 patients will be included. Study selection, data extraction, quality assessment, and assessment of risk bias will be performed by 2 reviewers independently. Odds ratios and correlative 95% confidence intervals will be calculated to present the association between the CM and CWM using Review Manager version 5.3 when there is sufficient available data.
RESULTS
The results will be disseminated through a peer-reviewed journal publication.
CONCLUSION
This systematic review findings will summarize up-to-date evidence for that CM is more effective and safe as adjunctive treatment for patients with COVID-19.
ETHICS AND DISSEMINATION
Ethics approval and patient consent are not required as this study is a systematic review based on published articles.
PROSPERO REGISTRATION NUMBER
CRD42020185382.
DOI: 10.1097/MD.0000000000021034
PubMed: 32871977
PubMed Central: PMC7437844
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chinese medicine for coronavirus disease 2019 as complementary therapy: A protocol for a systematic review and meta-analysis.</title>
<author><name sortKey="Zhou, Min" sort="Zhou, Min" uniqKey="Zhou M" first="Min" last="Zhou">Min Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>aCollege of Clinical Medical, Jiangxi University of Traditional Chinese Medicine bAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang cCollege of Clinical Medical, Shanghai University of Traditional Chinese Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>aCollege of Clinical Medical, Jiangxi University of Traditional Chinese Medicine bAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang cCollege of Clinical Medical, Shanghai University of Traditional Chinese Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liang, Qijun" sort="Liang, Qijun" uniqKey="Liang Q" first="Qijun" last="Liang">Qijun Liang</name>
</author>
<author><name sortKey="Pei, Qiulan" sort="Pei, Qiulan" uniqKey="Pei Q" first="Qiulan" last="Pei">Qiulan Pei</name>
</author>
<author><name sortKey="Xu, Fan" sort="Xu, Fan" uniqKey="Xu F" first="Fan" last="Xu">Fan Xu</name>
</author>
<author><name sortKey="Wen, Hang" sort="Wen, Hang" uniqKey="Wen H" first="Hang" last="Wen">Hang Wen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32871977</idno>
<idno type="pmid">32871977</idno>
<idno type="doi">10.1097/MD.0000000000021034</idno>
<idno type="pmc">PMC7437844</idno>
<idno type="wicri:Area/Main/Corpus">000401</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000401</idno>
<idno type="wicri:Area/Main/Curation">000401</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000401</idno>
<idno type="wicri:Area/Main/Exploration">000401</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chinese medicine for coronavirus disease 2019 as complementary therapy: A protocol for a systematic review and meta-analysis.</title>
<author><name sortKey="Zhou, Min" sort="Zhou, Min" uniqKey="Zhou M" first="Min" last="Zhou">Min Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>aCollege of Clinical Medical, Jiangxi University of Traditional Chinese Medicine bAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang cCollege of Clinical Medical, Shanghai University of Traditional Chinese Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>aCollege of Clinical Medical, Jiangxi University of Traditional Chinese Medicine bAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang cCollege of Clinical Medical, Shanghai University of Traditional Chinese Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liang, Qijun" sort="Liang, Qijun" uniqKey="Liang Q" first="Qijun" last="Liang">Qijun Liang</name>
</author>
<author><name sortKey="Pei, Qiulan" sort="Pei, Qiulan" uniqKey="Pei Q" first="Qiulan" last="Pei">Qiulan Pei</name>
</author>
<author><name sortKey="Xu, Fan" sort="Xu, Fan" uniqKey="Xu F" first="Fan" last="Xu">Fan Xu</name>
</author>
<author><name sortKey="Wen, Hang" sort="Wen, Hang" uniqKey="Wen H" first="Hang" last="Wen">Hang Wen</name>
</author>
</analytic>
<series><title level="j">Medicine</title>
<idno type="eISSN">1536-5964</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Complementary Therapies (methods)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Drugs, Chinese Herbal (therapeutic use)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Medicine, Chinese Traditional (methods)</term>
<term>Meta-Analysis as Topic (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Odds Ratio (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Prospective Studies (MeSH)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>Research Design (MeSH)</term>
<term>Systematic Reviews as Topic (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Mâle (MeSH)</term>
<term>Médecine traditionnelle chinoise (méthodes)</term>
<term>Médicaments issus de plantes chinoises (usage thérapeutique)</term>
<term>Méta-analyse comme sujet (MeSH)</term>
<term>Odds ratio (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Plan de recherche (MeSH)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Revues systématiques comme sujet (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Thérapies complémentaires (méthodes)</term>
<term>Études prospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Drugs, Chinese Herbal</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Complementary Therapies</term>
<term>Medicine, Chinese Traditional</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Médecine traditionnelle chinoise</term>
<term>Thérapies complémentaires</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Médicaments issus de plantes chinoises</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Betacoronavirus</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Meta-Analysis as Topic</term>
<term>Middle Aged</term>
<term>Odds Ratio</term>
<term>Pandemics</term>
<term>Prospective Studies</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Research Design</term>
<term>Systematic Reviews as Topic</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Betacoronavirus</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Méta-analyse comme sujet</term>
<term>Odds ratio</term>
<term>Pandémies</term>
<term>Plan de recherche</term>
<term>Revues systématiques comme sujet</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Études prospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>The aim of this systematic review and meta-analysis is to assess effectiveness and safety of Chinese medicine (CM) as complementary therapy in treating coronavirus disease 2019 (COVID-19).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>The following databases will be searched: PubMed, Cochrane, Embase, China National Knowledge Infrastructure, Chinese Science and Technology Periodical Database, and Wanfang database from October 1, 2019 to March 1, 2020. Randomized trials and quasi-randomized or prospective controlled clinical trials of CM that reported data on COVID-19 patients will be included. Study selection, data extraction, quality assessment, and assessment of risk bias will be performed by 2 reviewers independently. Odds ratios and correlative 95% confidence intervals will be calculated to present the association between the CM and CWM using Review Manager version 5.3 when there is sufficient available data.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The results will be disseminated through a peer-reviewed journal publication.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>This systematic review findings will summarize up-to-date evidence for that CM is more effective and safe as adjunctive treatment for patients with COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>ETHICS AND DISSEMINATION</b>
</p>
<p>Ethics approval and patient consent are not required as this study is a systematic review based on published articles.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>PROSPERO REGISTRATION NUMBER</b>
</p>
<p>CRD42020185382.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32871977</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>99</Volume>
<Issue>33</Issue>
<PubDate><Year>2020</Year>
<Month>Aug</Month>
<Day>14</Day>
</PubDate>
</JournalIssue>
<Title>Medicine</Title>
<ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
</Journal>
<ArticleTitle>Chinese medicine for coronavirus disease 2019 as complementary therapy: A protocol for a systematic review and meta-analysis.</ArticleTitle>
<Pagination><MedlinePgn>e21034</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000021034</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this systematic review and meta-analysis is to assess effectiveness and safety of Chinese medicine (CM) as complementary therapy in treating coronavirus disease 2019 (COVID-19).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The following databases will be searched: PubMed, Cochrane, Embase, China National Knowledge Infrastructure, Chinese Science and Technology Periodical Database, and Wanfang database from October 1, 2019 to March 1, 2020. Randomized trials and quasi-randomized or prospective controlled clinical trials of CM that reported data on COVID-19 patients will be included. Study selection, data extraction, quality assessment, and assessment of risk bias will be performed by 2 reviewers independently. Odds ratios and correlative 95% confidence intervals will be calculated to present the association between the CM and CWM using Review Manager version 5.3 when there is sufficient available data.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The results will be disseminated through a peer-reviewed journal publication.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This systematic review findings will summarize up-to-date evidence for that CM is more effective and safe as adjunctive treatment for patients with COVID-19.</AbstractText>
<AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="UNASSIGNED">Ethics approval and patient consent are not required as this study is a systematic review based on published articles.</AbstractText>
<AbstractText Label="PROSPERO REGISTRATION NUMBER" NlmCategory="UNASSIGNED">CRD42020185382.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>aCollege of Clinical Medical, Jiangxi University of Traditional Chinese Medicine bAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang cCollege of Clinical Medical, Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liang</LastName>
<ForeName>Qijun</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pei</LastName>
<ForeName>QiuLan</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>Fan</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wen</LastName>
<ForeName>Hang</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Medicine (Baltimore)</MedlineTA>
<NlmUniqueID>2985248R</NlmUniqueID>
<ISSNLinking>0025-7974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000529" MajorTopicYN="N">Complementary Therapies</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32871977</ArticleId>
<ArticleId IdType="doi">10.1097/MD.0000000000021034</ArticleId>
<ArticleId IdType="pii">00005792-202008140-00011</ArticleId>
<ArticleId IdType="pmc">PMC7437844</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Euro Surveill. 2020 Feb;25(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32046819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Evid Based Med. 2020 Feb;13(1):3-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32048815</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 26;382(13):1199-1207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31995857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Mar;92:214-217</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2020 May;26(5):1052-1054</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091386</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Feb 21;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32083643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Transl Med. 2020 Feb;8(3):48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32154288</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><noCountry><name sortKey="Liang, Qijun" sort="Liang, Qijun" uniqKey="Liang Q" first="Qijun" last="Liang">Qijun Liang</name>
<name sortKey="Pei, Qiulan" sort="Pei, Qiulan" uniqKey="Pei Q" first="Qiulan" last="Pei">Qiulan Pei</name>
<name sortKey="Wen, Hang" sort="Wen, Hang" uniqKey="Wen H" first="Hang" last="Wen">Hang Wen</name>
<name sortKey="Xu, Fan" sort="Xu, Fan" uniqKey="Xu F" first="Fan" last="Xu">Fan Xu</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Zhou, Min" sort="Zhou, Min" uniqKey="Zhou M" first="Min" last="Zhou">Min Zhou</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000792 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000792 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidSeniorV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32871977 |texte= Chinese medicine for coronavirus disease 2019 as complementary therapy: A protocol for a systematic review and meta-analysis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32871977" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidSeniorV1
![]() | This area was generated with Dilib version V0.6.37. | ![]() |